



**Citation:** Hammad M, Shubar AS (2021) HER2 Expression in Gastric Adenocarcinoma: A Study in a Tertiary Care Centre in Bahrain. J Cancer Diagn  
5:128

[5]. is family of genes contributes to most malignancies development. Each receptor of these consists of an extracellular ligand-binding domain, an intracellular domain with kinase activity and a short, lipophilic, trans-membrane domain [5,6]. Activation of any EGFR triggers a network of signaling cascade that promote tumor cell proliferation, migration, adhesion and angiogenesis and decrease in apoptosis [2]. HER2 does not bind to

---

## References

1. Penault-Llorca F, Chenard MP, Bouche O, Emile JF, Bibeau F, et al. (2011) HER2 and gastric cancer recommendations for clinical practice. *Ann Pathol* 31: 78-87.
2. Rüschof J, Hanna W, Bilous M, Hofmann M, Osamura RY, et al. (2012) HER2 testing in gastric cancer: A practical approach. *Mod Pathol* 25: 637-650.
3. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, et al. (2008) Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. *Histopathology* 52: 797-805.
4. Aditi R, Aarathi R, Pradeep R, Hemalatha L, Akshatha C, et al. (2016) HER2 expression in gastric adenocarcinoma: A study in a tertiary care centre in south India. *Indian J Surg Oncol* 7: 18-24.
5. Abuderman AA (2019) Gastric cancer and prospects of cancer in Saudi Arabia peninsula. *Saudi J Biol Sci* 26: 1095-1100.
6. Kelly CM, Janjigian YY (2016) The genomics and therapeutics of HER2 positive gastric cancer from trastuzumab and beyond. *J Gastrointest Oncol* 7: 750-762.
7. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. *Ann Oncol* 19: 1523-1529.
8. Omran BA, Ansari N (2015) Gastric cancer in Bahrain: A retrospective study of histologically confirmed tumours between 2001 and 2007 from the two main Bahraini referral hospitals. *O J Pathology* 5: 129-136.
9. Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, u HM015) WQ